New Media Department           Yu Jie, Duan Yuqing           May 6, 2021

On May 1, the innovative bispecific antibody F182112 developed by Lunan Pharma was successfully approved by the FDA for clinical trial.

F182112 is an innovative biological drug for the treatment of multiple myeloma (MM). MM is the second most common cancer of the blood, accounting for about 10% of hematological malignancies, mostly in the elderly and still incurable at present. The incidence of multiple myeloma in China is increasing year by year, and the age of onset is getting younger. With the improvement of diagnostic methods, although the survival rate of patients has been improved by the new treatment methods, the increasing population and the aggravation of population aging have led to the increasing prevalence of MM.

Over the past decade or so, the focus of treatment has shifted from harsh systemic treatments such as chemotherapy to more targeted treatments such as immunotherapy. F182112 is highly specific for MM and plays an important role in multiple myeloma as well as relapsed/refractory multiple myeloma.

As a leading innovation-driven comprehensive pharmaceutical group in China, Lunan Pharma has a complete research platform for traditional Chinese medicine, chemical medicine and biological medicine. In recent years, the company has continuously strengthened its innovation efforts, and now more than 10 innovative biological drugs are in clinical trials and different pre-clinical research stages. This clinical approval means that Lunan Pharma's innovative drug research and development has gone into the main international battlefield!